Clinical trial
Pharmacokinetic and Pharmacodynamic Evaluation of 3 Standard Formulations of Δ9-THC in Healthy Volunteers and Post-chemotherapy Patients in Colombia
Name
1171735
Description
Study based on the pharmacokinetic, pharmacodynamic, safety and stability evaluation of 3 standardized formulations of THC, to be used in healthy volunteers and post-chemotherapy patients as an adjuvant in the symptomatic treatment of the latter in discomfort associated with cancer treatment, with the aim of possible new therapeutic entities.
Trial arms
Trial start
2023-08-15
Estimated PCD
2024-02-15
Trial end
2024-10-17
Status
Not yet recruiting
Phase
Early phase I
Treatment
Pharmacokinetic and pharmacodynamic profile of THC oral formulations with Dronabinol as comparator
Assessment of Pharmacokinetic and pharmacodynamic profile of THC oral formulations in 4 arms in healthy volunteers and patients post-chemotherapy.
Arms:
Dronabinol 5mg/mL, THC F1, THC F2, THC F3
Other names:
Administration of different Cannabis oral formulations with THC as compared with Active comparator (DRONABINOL)
Size
334
Primary endpoint
Pharmacokinetic assessment profile of THC formulations
48 hours with a replicate 7 days after the first dose in healthy subjects and the same time but with successive doses in post-chemotherapy patients
Pharmacodynamic assessment profile of THC formulations: BPI
Post-chemotherapy patients for at least 20 days with a daily report
Pharmacodynamic assessment profile of THC formulations: DEQ
48 hours with a replicate of 7 days after the first dose in healthy subjects and on the other hand post-chemotherapy patients for at least 20 days with a daily report
No significant nausea in terms of the proportion of subjects with no significant nausea
Post-chemotherapy patients for at least 20 days with a daily report
Eligibility criteria
Inclusion Criteria:
Inclusion criteria for healthy volunteers
In order to be eligible to be admitted to this study, healthy volunteers must:
1. Being a person \> 18 years of age
2. Have the ability to understand the requirements of the study and be willing to give written informed consent
3. Agree to abide by study restrictions and return for required evaluations.
4. Signed written informed consent.
Inclusion criteria for patients
In order to be eligible to be admitted to this study, patients must:
1. Being a person \> 18 years of age
2. Be a patient with documented chemotherapy treatment.
3. Patients with any of the following cancers: breast, prostate, lung, colorectal, cervical, gastric and liver cancer.
4. Have a life expectancy \>1 year
5. Have the ability to understand the requirements of the study and be willing to give written informed consent
6. Agree to abide by study restrictions and return for required evaluations
Exclusion Criteria:
Exclusion criteria for healthy volunteers
To be eligible to be admitted to this study, the participant and/or patient must not:
1. Recreational or medicinal use of cannabinoids in the last 3 months.
2. Uses of current medications such as: immunomodulators, antibiotics, corticosteroids
3. Hypersensitivity to any component of the investigational product.
4. Patients prescribed dronabinol between arrival and prior to screening/randomization
5. Pregnancy or lactation
6. Liver pathologies and/or CYP2A3, CYP2C9 and CYP2C19 polymorphisms
7. Opioid hypersensitivity
8. Obesity
9. Patients who have undergone concomitant immunotherapy with chemotherapy
10. Cannabinoid Hyperemesis Syndrome (CHS).
Exclusion criteria for patients
To be eligible to be admitted to this study, the participant and/or patient must not:
1. Patients who are null by mouth (NPO) at the time of randomization or who are expected to be NPO within the next 48 hours
2. Patients who have received or are expected to receive neuraxial/locoregional blocks for pain in the next 48 hours.
3. Recreational or medicinal use of cannabinoids in the last 3 months.
4. Uses of current medications such as: immunomodulators, antibiotics, corticosteroids
5. Hypersensitivity to any component of the investigational product.
6. Patients prescribed dronabinol between arrival and prior to screening/randomization
7. Pregnancy or lactation
8. Liver pathologies and/or CYP2A3, CYP2C9 and CYP2C19 polymorphisms
9. Opioid hypersensitivity
10. Obesity
11. Patients who have undergone concomitant immunotherapy with chemotherapy
12. Cannabinoid Hyperemesis Syndrome (CHS). -
Protocol
{'studyType': 'INTERVENTIONAL', 'phases': ['PHASE1', 'PHASE2'], 'designInfo': {'allocation': 'RANDOMIZED', 'interventionModel': 'PARALLEL', 'primaryPurpose': 'OTHER', 'maskingInfo': {'masking': 'NONE'}}, 'enrollmentInfo': {'count': 334, 'type': 'ESTIMATED'}}
Updated at
2023-02-01
1 organization
1 product
5 indications
Organization
LaSantaProduct
THC oral formulationsIndication
Nausea Post ChemotherapyIndication
VomitingIndication
Cancer PainIndication
Cancer Related PainIndication
Cancer